Bristol Myers Squibb's Zenbexus Combination Shows Improved Progression-Free Survival in Phase 3 Trial
MT newswire2026/10/08 11:5507:55 AM EDT, 10/08/2026 (MT Newswires) -- Bristol Myers Squibb (BMY) said Thursday that a phase 3 study evaluating Zenbexustm in combination with daratumumab and dexamethasone in 800 patients with relapsed or refractory multiple myeloma showed a statistically significant improvement in the dual-primary endpoint of progression-free survival. The trial evaluated dual-primary endpoints of minimal residual disease-negative complete response and progression-free survival. Secondary endpoints included overall survival, overall response rate, safety and sustained minimal residual disease negativity, the company said. The company previously reported improvement in the other dual-primary endpoint compared with the control regimen. That result supported the FDA's accelerated approval of Zenbexus for relapsed or refractory multiple myeloma. Median progression-free survival was 42 months for the Zenbexus combination, compared with 20 months for daratumumab, bortezomib and dexamethasone. The result represented a 51% reduction in the risk of disease progression or death, Bristol Myers said. Median follow-up was 23 months. The safety profile of Zenbexustm in combination with standard therapies was consistent with prior findings, the company said.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Is the US dollar peaking or just taking a breather? Major banks hold divergent views
US and European bond markets: yields turn higher
Euro is Undervalued and ECB Succession Issues — ING Perspectives
Eurozone investor confidence slightly declined in November
Crypto prices
More
